A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Clinical trial NCT05320692 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05320692
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-09
- Primary completion
- 2026-07-30
- Enrollment
- 423
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.